Drug intelligence / Profile preview

H-15

Development stage: Preclinical
Lead developer: Aichi Cancer Center
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

H-15 is an IgG1 mouse monoclonal antibody (mAb) that targets a cell surface antigen with a molecular mass of 200,000 daltons. This antigen is present on virtually all colorectal cancers, as well as in normal pancreatic and bile ducts, but not in other normal tissues. When labeled with Iodine-131 (131I), H-15 is used for radioimmunodetection, demonstrating selective localization to tumor tissues. It is valuable for differentiating recurrent colorectal cancer from granuloma formation after surgery.

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on H-15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H-15.

Explore the full profile